121 related articles for article (PubMed ID: 1422313)
21. Effects of intravenous pamidronate therapy on Paget's disease of bone.
Bombassei GJ; Yocono M; Raisz LG
Am J Med Sci; 1994 Oct; 308(4):226-33. PubMed ID: 7942981
[TBL] [Abstract][Full Text] [Related]
22. The effects of intravenous alendronate in Paget's disease of bone.
O'Doherty DP; McCloskey EV; Vasikaran S; Khan S; Kanis JA
J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
[TBL] [Abstract][Full Text] [Related]
23. Pamidronate sodium and calcitonin-resistant Paget's disease. Immediate response in a patient.
Drake S; Massie JD; Postlethwaite AE; Palmieri GM
Arch Intern Med; 1989 Feb; 149(2):401-3. PubMed ID: 2783843
[TBL] [Abstract][Full Text] [Related]
24. Phosphate depletion in the rat: effect of bisphosphonates and the calcemic response to PTH.
Jara A; Lee E; Stauber D; Moatamed F; Felsenfeld AJ; Kleeman CR
Kidney Int; 1999 Apr; 55(4):1434-43. PubMed ID: 10201008
[TBL] [Abstract][Full Text] [Related]
25. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
26. Cyclical pamidronate infusions in postmenopausal osteoporosis.
Peretz A; Body JJ; Dumon JC; Rozenberg S; Hotimski A; Praet JP; Moris M; Ham H; Bergmann P
Maturitas; 1996 Aug; 25(1):69-75. PubMed ID: 8887311
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Paget's disease of bone with single dose intravenous pamidronate.
Watts RA; Skingle SJ; Bhambhani MM; Pountain G; Crisp AJ
Ann Rheum Dis; 1993 Aug; 52(8):616-8. PubMed ID: 8215628
[TBL] [Abstract][Full Text] [Related]
28. [Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism].
Kotzmann H; Svoboda T; Bernecker P; Clodi M; Woloszczuk W; Niederle B; Waldhäusl W; Luger A
Wien Klin Wochenschr; 1994; 106(13):422-5. PubMed ID: 8091766
[TBL] [Abstract][Full Text] [Related]
29. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.
Papapoulos SE; Harinck HI; Bijvoet OL; Gleed JH; Fraher LJ; O'Riordan JL
Bone Miner; 1986 Feb; 1(1):69-78. PubMed ID: 3508718
[TBL] [Abstract][Full Text] [Related]
30. Changes in calcium homoeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively.
Bishop NJ; Ninkovic M; Alexander GJ; Holmes SD; Milligan T; Price C; Compston JE
Clin Sci (Lond); 1999 Aug; 97(2):157-63. PubMed ID: 10409470
[TBL] [Abstract][Full Text] [Related]
31. [A single infusion of Pamidronate (APD) in Paget's disease of bone].
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
Schweiz Med Wochenschr; 1989 Jan; 119(3):71-4. PubMed ID: 2711157
[TBL] [Abstract][Full Text] [Related]
32. Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the bisphosphonate pamidronate.
Landman JO; Schweitzer DH; Frölich M; Hamdy NA; Papapoulos SE
J Clin Endocrinol Metab; 1995 Feb; 80(2):524-8. PubMed ID: 7852514
[TBL] [Abstract][Full Text] [Related]
33. Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancer.
Berruti A; Sperone P; Fasolis G; Torta M; Fontana D; Dogliotti L; Angeli A
Prostate; 1997 Dec; 33(4):252-5. PubMed ID: 9397197
[TBL] [Abstract][Full Text] [Related]
34. Pamidronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.
Yaghoobian J; Morieux C; Denne MA; Bouizar Z; Ureña P; de Vernejoul MC
Horm Metab Res; 1998 May; 30(5):249-55. PubMed ID: 9660083
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.
Douglas DL; Duckworth T; Kanis JA; Preston C; Beard DJ; Smith TW; Underwood I; Woodhead JS; Russell RG
Arthritis Rheum; 1980 Oct; 23(10):1185-92. PubMed ID: 6448604
[TBL] [Abstract][Full Text] [Related]
36. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
[TBL] [Abstract][Full Text] [Related]
37. The effect of alendronate on renal tubular reabsorption of phosphate.
Vasikaran SD; O'Doherty DP; McCloskey EV; Gertz B; Kahn S; Kanis JA
Bone Miner; 1994 Oct; 27(1):51-6. PubMed ID: 7849546
[TBL] [Abstract][Full Text] [Related]
38. Tubular excretion of phosphate in Paget's disease of bone. Effect of pamidronate.
Constantin A; Laroche M; Moulinier L; Bon E; Ramonjisoa M; Cantagrel A; Mazieres B
Rev Rhum Engl Ed; 1995; 62(7-8):493-500. PubMed ID: 8574612
[TBL] [Abstract][Full Text] [Related]
39. Effects of fasting, feeding, and bisphosphonate administration on serum calcitriol levels in phosphate-deprived rats.
Felsenfeld AJ; Jara A; Avedian G; Kleeman CR
Kidney Int; 2000 Sep; 58(3):1016-22. PubMed ID: 10972666
[TBL] [Abstract][Full Text] [Related]
40. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate).
Fraser TR; Ibbertson HK; Holdaway IM; Rutland M; King A; Dodd G; Wattie DJ
Aust N Z J Med; 1984 Dec; 14(6):811-8. PubMed ID: 6442563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
